DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Niesvizky R, Badros AZ, Costa LJ, Ely SA, Singhal SB, Stadtmauer EA. et al.
phase 1/2 study of cyclin-dependent kinase (CDK) 4/6 inhibitor palbociclib (pD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
Leuk Lymphoma 2015;
56: 3320-8
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.